Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry

EMERYVILLE, Calif., May 22, 2017 (GLOBE NEWSWIRE) — Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that new data on the mechanism of action of ZX008 was presented in a poster at the 72nd Annual Meeting of the Society of Biological Psychiatry, held May 18 – 20, 2017, in San Diego, CA (see study data here).  ZX008 (low-dose fenfluramine) is being developed as an adjunctive treatment for Dravet syndrome (DS), a rare epileptic encephalopathy.